[DRUG USE DURING PREGNANCY AFTER DISCOVERY OF THALIDOMIDE EMBRYOPATHY].
D000014:Abnormalities, Drug-Induced; D000700:Analgesics; D018712:Analgesics, Non-Narcotic; D058633:Antipyretics; D004480:Ectromelia; D005260:Female; D005315:Fetal Diseases; D006801:Humans; D006993:Hypnotics and Sedatives; D008431:Maternal-Fetal Exchange; D008468:Meclizine; D009790:Occupations; D004364:Pharmaceutical Preparations; D010633:Phenmetrazine; D011247:Pregnancy; D012924:Social Conditions; D013223:Statistics as Topic; D013577:Syndrome; D013792:Thalidomide
D000700:Analgesics; D018712:Analgesics, Non-Narcotic; D058633:Antipyretics; D006993:Hypnotics and Sedatives; D004364:Pharmaceutical Preparations; D008468:Meclizine; D013792:Thalidomide; D010633:Phenmetrazine
ABNORMALITIES, DRUG-INDUCED; ANALGESICS AND ANTIPYRETICS; DRUGS; ECTROMELIA; HYPNOTICS AND SEDATIVES; MATERNAL-FETAL EXCHANGE; MECLIZINE; OCCUPATIONS; PHENMETRAZINE; PREGNANCY; SOCIAL CONDITIONS; STATISTICS; THALIDOMIDE
ARZNEIMITTELVERBRAUCH IN DER SCHWANGERSCHAFT NACH AUFKLAERUNG DER  THALIDOMID-EMBRYOPATHIE.